Hypertension among people living with HIV/AIDS in Cameroon: A cross-sectional analysis from Central Africa International Epidemiology Databases to Evaluate AIDS

Background Antiretroviral therapy (ART) success has led people to live longer with HIV/AIDS (PLWH) and thus be exposed to increasing risk of cardiovascular diseases (CVD). Hypertension (HTN), the biggest contributor to CVD burden, is a growing concern among PLWH. The current report describes the prevalence and predictors of HTN among PLWH in care in Cameroon. Methods This crosssectional study included all PLWH aged 20 years and above who received care between 2016 and 2019 at one of the three Central Africa International Epidemiology Databases to Evaluate AIDS (CAIeDEA) sites in Cameroon (Bamenda, Limbe, and Yaounde). HTN was defined as blood pressure (BP) [≥]140/90 mm Hg or self reported use of antihypertensive medication. Logistic regressions models examined the relationship between HTN and clinical characteristics, and HIV related factors. Results Among 9,839 eligible PLWH, 66.2% were female and 25.0% had prevalent HTN [age standardized prevalence 23.9% (95% CI: 22.2: 25.6)], among whom 28 (1.1%) were on BP lowering treatment, and 6 of those (21.4%) were at target BP levels. Median age (47.4 vs. 40.5 years), self reported duration of HIV infection (5.1 vs 2.8 years), duration of ART exposure (4.7 vs 2.3 years), and CD4 count (408 vs 359 cell/mm3) were higher in hypertensives than non hypertensives (all p<0.001). Age and body mass index (BMI) were independently associated with higher prevalent HTN risk. PLWH starting ART had a 30% lower risk of prevalent HTN, but this advantage disappeared after a cumulative 2 year exposure to ART. There was no significant association between other HIV predictive characteristics and HTN. Conclusion About a quarter of these Cameroonian PLWH had HTN, driven among others by age and adiposity. Appropriate integration of HIV and NCDs services is needed to improve early detection, treatment and control of common comorbid NCD risk factors like hypertension and safeguard cardiovascular health in PLWH.

[1]  Audrey Joyce Foka,et al.  Global burden of hypertension among people living with HIV in the era of increased life expectancy: a systematic review and meta-analysis. , 2020, Journal of hypertension.

[2]  S. Ameh.  Evaluation of an integrated HIV and hypertension management model in rural South Africa: a mixed methods approach , 2020, Global health action.

[3]  A. Kengne,et al.  Availability, cost and affordability of essential cardiovascular disease medicines in the south west region of Cameroon: Preliminary findings from the Cameroon science for disease study , 2020, PloS one.

[4]  Nan-fang Li,et al.  Excess weight loss is a vital strategy for controlling hypertension among multi-ethnic population in northwest China , 2019, Medicine.

[5]  Lionel Ngamani,et al.  Implementation of a REDCap-Based Research Data Collection System in Cameroon , 2019, MedInfo.

[6]  A. R. Akiteng,et al.  Integrated Hypertension and HIV Care Cascades in an HIV Treatment Program in Eastern Uganda: a retrospective cohort study. , 2019, Journal of acquired immune deficiency syndromes.

[7]  A. Kengne,et al.  MMM17-Cameroon, analysis and opportunities—Sub-Saharan Africa , 2019, European heart journal supplements : journal of the European Society of Cardiology.

[8]  N. Crowther,et al.  Prevalence, incidence, predictors, treatment, and control of hypertension among HIV-positive adults on antiretroviral treatment in public sector treatment programs in South Africa , 2018, PloS one.

[9]  Thomas Kahan,et al.  [2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)]. , 2018, Giornale italiano di cardiologia.

[10]  A. Kengne,et al.  Prevalence, detection, treatment, and control of hypertension in human immunodeficiency virus (HIV)-infected patients attending HIV clinics in the Western Cape Province, South Africa , 2018, Medicine.

[11]  D. Prabhakaran,et al.  May Measurement Month 2017: an analysis of blood pressure screening results worldwide. , 2018, The Lancet. Global health.

[12]  K. Sliwa,et al.  Roadmap to achieve 25% hypertension control in Africa by 2025 , 2017, Cardiovascular journal of Africa.

[13]  Xinguang Chen,et al.  Global prevalence of hypertension among people living with HIV: a systematic review and meta-analysis. , 2017, Journal of the American Society of Hypertension : JASH.

[14]  K. Sliwa,et al.  Roadmap to Achieve 25% Hypertension Control in Africa by 2025. , 2018, Global heart.

[15]  B. Gazzard,et al.  Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV‐Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial , 2017, Journal of the American Heart Association.

[16]  A. Fauci,et al.  Association Between Human Immunodeficiency Virus Infection and Cardiovascular Diseases: Finding a Solution to Double Jeopardy. , 2017, JAMA cardiology.

[17]  E. Mills,et al.  Trends and level of control of hypertension among adults attending an ambulatory HIV clinic in Kampala, Uganda: a retrospective study , 2016, BMJ Global Health.

[18]  W. Fawzi,et al.  Prevalence of Hypertension and Its Associated Risk Factors among 34,111 HAART Naïve HIV-Infected Adults in Dar es Salaam, Tanzania , 2016, International journal of hypertension.

[19]  Ashutosh Kumar Singh,et al.  Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2016, The Lancet.

[20]  M. Egger,et al.  Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: comparisons with general population , 2016, Current opinion in HIV and AIDS.

[21]  D. Ekouevi,et al.  High prevalence of being Overweight and Obese HIV-infected persons, before and after 24 months on early ART in the ANRS 12136 Temprano Trial , 2016, AIDS Research and Therapy.

[22]  J. Atashili,et al.  Prevalence of Hypertension in HIV/AIDS Patients on Highly Active Antiretroviral Therapy (HAART) Compared with HAART-Naïve Patients at the Limbe Regional Hospital, Cameroon , 2016, PloS one.

[23]  M. Ngowe,et al.  Risk Factors of Cardiovascular Diseases in HIV/AIDS Patients on HAART , 2015, The open AIDS journal.

[24]  Betrand N Fesuh,et al.  Prevalence and Risk Factors of Hypertension in Urban Areas of Cameroon: A Nationwide Population‐Based Cross‐Sectional Study , 2015, Journal of clinical hypertension.

[25]  S. Haneuse,et al.  Incidence and predictors of hypertension in adults with HIV-initiating antiretroviral therapy in south-western Uganda , 2015, Journal of hypertension.

[26]  A. Kengne,et al.  Burden, Determinants, and Pharmacological Management of Hypertension in HIV-Positive Patients and Populations: A Systematic Narrative Review. , 2015, AIDS reviews.

[27]  A. Kengne,et al.  Coincidence of diabetes mellitus and hypertension in a semi-urban Cameroonian population: a cross-sectional study , 2014, BMC Public Health.

[28]  P. van de Borne,et al.  Increased burden and severity of metabolic syndrome and arterial stiffness in treatment-naïve HIV+ patients from Cameroon , 2013, Vascular health and risk management.

[29]  A. Kengne,et al.  Peer Review History Title (provisional) Prevalence, Awareness, Treatment and Control of Hypertension in a Self-selected Sub-saharan African Urban Population: a Cross- Sectional Study , 2022 .

[30]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[31]  C. Jericó,et al.  Hypertension in HIV-infected patients: prevalence and related factors. , 2005, American journal of hypertension.

[32]  C. Shikuma,et al.  Elevated Blood Pressure in HIV-Infected Individuals Receiving Highly Active Antiretroviral Therapy , 2003, HIV clinical trials.

[33]  Thomas Kahan,et al.  [2018 ESC/ESH Guidelines for the management of arterial hypertension]. , 2019, Kardiologia polska.